COMP <GO>
NHC vs ABBV // GROSS PROFIT MARGIN
National HealthCare Corporation (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: NHC 7
— ABBV 5
■ METRIC PARITY
LAST: $212.16 (+0.18%) • MKT CAP: $3.32B
gross-margins
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NHC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NHC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.10% | 29.00% | -18.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.5x | 33.3x | -12.80 | NHC | /valuation <GO> |
| Free Cash Flow Yield | 4.47% | 3.47% | +1.00 | NHC | /fcf-yield <GO> |
| Operating Margin | 8.50% | 24.60% | -16.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 7.90% | 6.90% | +1.00 | NHC | /net-margins <GO> |
| Revenue Growth (YoY) | 16.10% | 8.60% | +7.50 | NHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.16% | 2.27% | -1.11 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.61 | 5.33 | +1.28 | NHC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | NHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.1 | 65.1 | -30.00 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.3x | 113.1x | -89.80 | NHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.32B | $513.86B | -$510.54B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NHC REV | ABBV REV | NHC GROSS % | ABBV GROSS % | NHC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.52B | $61.16B | — | 70.2% | $148.6M | $17.82B |
| FY 2024 | $1.31B | $56.33B | — | 70.0% | $79.7M | $17.83B |
| FY 2023 | $1.14B | $54.32B | — | — | $111.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NHC // BETA —
ABBV // BETA 1.15